drugset / Trial / NCT04917042
Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.
Timeline
- Start
- 2021-08-25
- Primary completion
- 2025-02-14
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tazemetostat | Small molecule | 520 mg/m2 | Oral |
| Subject | Tazemetostat | Small molecule | 800 mg | Oral |